September 25, 2018 10:19 AM EDTUpdated 11:34 AM
News Briefing

Take­da high­lights promis­ing front­line re­sults for ALK+ NSCLC drug Alun­brig; TGTX shares plunge on PhI­II sna­fu

John Carroll

Editor & Founder

→ Take­da un­veiled pos­i­tive PFS da­ta for its ALK+ NSCLC drug Alun­brig (briga­tinib) to­day, un­der­scor­ing a haz­ard ra­tio of 0.49 — a 51% drop in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

Biotech VC firm out­lines plans for $100M fund

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

FDA ap­proves Zevra’s rare dis­ease drug af­ter re­sub­mis­sion

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times